Avanstra

Avanstra is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics for central nervous system (CNS) disorders. The company's lead candidate, AVN-101, is a multi-target medicinal agent designed to treat Alzheimer's disease and generalized anxiety disorder by modulating various serotonin and dopamine receptors. Avanstra aims to address significant unmet medical needs in neurology and psychiatry through its pipeline of CNS-targeted compounds. The company operates with a focus on optimizing the pharmacological profiles of its candidates to improve efficacy and safety compared to existing treatments. Headquartered in San Diego, Avanstra was established to leverage advanced medicinal chemistry and pharmacology to create next-generation CNS therapies. The company has historically received backing from specialized life science investors such as the Maxwell Biotech Venture Fund.